BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 26376844)

  • 1. Immunotherapies in Early and Advanced Renal Cell Cancer.
    Kasenda B; Larkin J; Gore M
    Prog Tumor Res; 2015; 42():1-10. PubMed ID: 26376844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
    Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
    Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current immunotherapeutic strategies in renal cell carcinoma.
    Amato RJ
    Surg Oncol Clin N Am; 2007 Oct; 16(4):975-86, xi-xii. PubMed ID: 18022554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint inhibitors as novel targets for renal cell carcinoma therapeutics.
    Bailey A; McDermott DF
    Cancer J; 2013; 19(4):348-52. PubMed ID: 23867517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccines for melanoma and renal cell carcinoma.
    Kaufman HL
    Semin Oncol; 2012 Jun; 39(3):263-75. PubMed ID: 22595049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel immunotherapeutic strategies in development for renal cell carcinoma.
    Inman BA; Harrison MR; George DJ
    Eur Urol; 2013 May; 63(5):881-9. PubMed ID: 23084331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety and efficacy of nivolumab for the treatment of advanced renal cell carcinoma.
    Ornstein MC; Rini BI
    Expert Rev Anticancer Ther; 2016 Jun; 16(6):577-84. PubMed ID: 27144724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent developments in renal cell cancer immunotherapy.
    Wysocki PJ; Zolnierek J; Szczylik C; Mackiewicz A
    Expert Opin Biol Ther; 2007 May; 7(5):727-37. PubMed ID: 17477809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccine therapy in patients with renal cell carcinoma.
    Van Poppel H; Joniau S; Van Gool SW
    Eur Urol; 2009 Jun; 55(6):1333-42. PubMed ID: 19201522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials.
    Lenis AT; Donin NM; Johnson DC; Faiena I; Salmasi A; Drakaki A; Belldegrun A; Pantuck A; Chamie K
    J Urol; 2018 Jan; 199(1):43-52. PubMed ID: 28479237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma.
    Flippot R; Escudier B; Albiges L
    Drugs; 2018 Sep; 78(14):1443-1457. PubMed ID: 30187355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New therapeutic developments in renal cell cancer.
    Prenen H; Gil T; Awada A
    Crit Rev Oncol Hematol; 2009 Jan; 69(1):56-63. PubMed ID: 18752971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nivolumab in the treatment of advanced renal cell carcinoma.
    Arasaratnam M; Gurney H
    Future Oncol; 2018 Jul; 14(17):1679-1689. PubMed ID: 29460635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging monoclonal antibodies for the treatment of renal cell carcinoma (RCC).
    Atkins MB; Philips GK
    Expert Opin Emerg Drugs; 2016 Sep; 21(3):243-54. PubMed ID: 27539246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
    Ott PA; Hodi FS; Robert C
    Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines.
    Wang Y; Wang XY; Subjeck JR; Shrikant PA; Kim HL
    Br J Cancer; 2011 Feb; 104(4):643-52. PubMed ID: 21285988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy of Melanoma.
    Snyder A; Zamarin D; Wolchok JD
    Prog Tumor Res; 2015; 42():22-9. PubMed ID: 26376963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant and adjuvant strategies in renal cell carcinoma: more questions than answers.
    Homicsko K; Berthold DR
    Anticancer Drugs; 2011 Jan; 22 Suppl 1():S4-8. PubMed ID: 21173604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapeutic strategies for the treatment of renal cell carcinoma: where are we now?
    Bedke J; Stenzl A
    Expert Rev Anticancer Ther; 2013 Dec; 13(12):1399-408. PubMed ID: 24215158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-angiogenic therapy in renal cell cancer.
    Srinivasan R; Armstrong AJ; Dahut W; George DJ
    BJU Int; 2007 May; 99(5 Pt B):1296-300. PubMed ID: 17441927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.